TPI1 and neoplasm: The rationale for combined therapy is that TPI downregulates TYMP and turns tumor cells immunogenic via induction of immunogenic cell death (ICD) to present tumor antigens to DCs to recruit T cells and modulate tumor-infiltrating lymphocytes (TILs).